In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works. Elri Voigt goes over the new findings and unpacks the licenses that are expected to facilitate the availability of generic versions of the jab in over a hundred countries, including South Africa.
Inside Professor Linda-Gail Bekker’s office a bookshelf is stacked with titles on general medicine, HIV and tuberculosis. Against the bookshelf, a mannequin leans dressed in a white doctor’s coat, sparkling tiara and pink Venetian mask, with a stethoscope protruding from her pocket. Known to colleagues as LGB, Bekker is one of South Africa’s top HIV researchers. Biénne Huisman chatted to Bekker about her remarkable career, finding new ways to reach young people, her love of both art and science and the thinking behind the slogan “get ripped, get prepped”.
Last year Spotlight reported that pilot projects testing out a new HIV prevention injection and a vaginal ring in South Africa would start early in 2023. Yet, as delegates gathered for the SA AIDS Conference in Durban last week, those pilots hadn’t yet started. Alicestine October and Elri Voigt have the latest on the state of play with these critical projects.
